Immix Biopharma Inc Stock Price, News & Analysis

Immix Biopharma (Nasdaq: IMMX) has initiated Good Manufacturing Practice (GMP) manufacturing for IMX-120, a biologic targeting inflammatory bowel disease (IBD). The company plans to file an Investigational New Drug (IND) application for IMX-120 in 2023, marking an important milestone for future clinical trials. The IBD market is projected to grow from $18.4 billion in 2019 to $21.4 billion by 2024, underscoring the potential market opportunity for IMX-120. This development highlights ImmixBio's commitment to advancing treatment options in the biopharmaceutical sector.

Immix Biopharma has hosted an Investors Day event on February 1, 2022, where management responded to top-voted questions from verified shareholders. The session highlighted the company’s commitment to transparency and ongoing communication with investors. ImmixBio is focused on its lead asset, IMX-110, currently in Phase 1b/2a clinical trials for soft tissue sarcoma and rhabdomyosarcoma, supported by orphan drug and rare pediatric designations by the FDA.

Immix Biopharma, Inc. (Nasdaq: IMMX) announced the initiation of Good Manufacturing Practice (GMP) scale-up for IMX-110, marking a significant step toward accelerating two clinical trials planned for 2022. The first trial focuses on IMX-110 monotherapy for soft tissue sarcoma, while the second tests the combination of IMX-110 with BeiGene's anti-PD-1 tislelizumab for advanced solid tumors. IMX-110 has received orphan drug and rare pediatric disease designations from the FDA, enabling fast-track review for its marketing approval.

Immix Biopharma, Inc. (Nasdaq: IMMX) reports promising data on IMX-110 in combination with anti-PD-1, achieving a 63-day median survival in a KPC pancreatic cancer mouse model, compared to the historical median of 42 days from a standard 4-drug regimen. This significant result underlines the potential of IMX-110, which is set to enter a Phase 1b/2a clinical trial with BeiGene's tislelizumab in advanced solid tumors in 2022. The FDA has granted orphan drug and rare pediatric disease designations for IMX-110, positioning it well for future clinical advancements.

Immix Biopharma (Nasdaq: IMMX) announced positive interim results from its Phase 1b/2a clinical trial of IMX-110 for soft tissue sarcoma (STS), reporting 100% of patients completed planned treatment cycles without drug-related interruptions. This contrasts with the historical completion rates of 43-67% for existing STS treatments. IMX-110 holds orphan drug and rare pediatric disease designations from the FDA, which may facilitate faster regulatory review. The STS market is projected to grow from $3 billion to $6.5 billion by 2030.

Immix Biopharma reported promising results for its lead candidate IMX-110, demonstrating a 50% response rate in a study involving first-line-therapy-resistant soft tissue sarcoma (STS) mice, outperforming the standard treatment doxorubicin’s 0% response rate. This candidate is positioned in a lucrative market projected to grow from $2.9 billion in 2019 to $6.5 billion by 2030. Additionally, IMX-110 has received orphan drug and rare pediatric disease designations from the FDA, which could expedite its development and approval process.

Immix Biopharma, Inc. (Nasdaq: IMMX) announced the IMMX Investors Day Event on February 1, 2022. An online Q&A platform is open for shareholders to submit questions until January 20. The live event will be webcasted on the Investor Relations website, and a replay will be provided afterward. ImmixBio specializes in Tissue Specific Therapeutics (TSTx) for oncology and immuno-dysregulated diseases, with a proprietary platform that enhances drug delivery. Investors are encouraged to participate and engage with management during this event.

Immix Biopharma (Nasdaq: IMMX) has received Rare Pediatric Disease Designation from the FDA for IMX-110, aimed at treating rhabdomyosarcoma, a life-threatening pediatric cancer. This designation may allow the company to obtain a Priority Review Voucher (PRV) upon marketing approval, potentially valued between $67 million to $350 million. IMX-110 is currently in a Phase 1b/2a clinical trial and has shown promising data, including a median progression-free survival of four months with no severe drug-related adverse events.

Immix Biopharma, Inc. (Nasdaq: IMMX) has successfully closed its initial public offering (IPO) of 4.2 million shares at $5.00 per share, raising $21 million. An additional 630,000 shares may be purchased by underwriters for over-allotments. The funds will support clinical trials for IMX-110 and other IND-enabling studies. The shares began trading on the Nasdaq Capital Market on December 16, 2021. ThinkEquity acted as the book-running manager for the offering. The company focuses on developing Tissue Specific Therapeutics for oncology and immuno-dysregulated diseases.